伊立替康联合卡培他滨治疗晚期胃癌的临床观察

目的 评价伊立替康联合卡培他滨在晚期胃癌治疗中的有效性和安全性.方法 34例晚期胃癌患者,给予伊立替康100 mg/m2静脉注射（第1、8天）;卡培他滨1000 mg/m2,每日2次,口服（第1～14天）,每21天为一个周期,3个周期后评价疗效.结果 34例患者中1例因经济原因,只化疗1个周期,另外1例出现消化道出血,化疗1.5个周期.无完全缓解病例,部分缓解（PR）占53.1%（17/32）,稳定（SD）占18.8%（6/32）,进展（PD）占28.1%（9/32）,中位疾病进展时间为6个月,中位生存时间为10个月.不良反应主要有腹泻、恶心、呕吐、骨髓抑制,多为Ⅰ、Ⅱ度.结论 伊立替康联合卡培他滨对晚期胃癌有效,不良反应可以耐受.

Treatment of advanced gastric cancer with the regimen of Iriontecan combined with Capecitabine

Objective To evaluate the efficacy and safety of irinotecan and capeeitabine combination chemotherapy in patients with advanced gastric cancer. Methods Thirty - four patients with advanced gastric cancer received irinntecan 100 mg/m2 intravenous infusion （dl, d8）with oral capecitabine 1000 mg/m2 twice daily （dl - d14） , with every 3 weeks as a circle. The effect can be evaluated after 3 cycles. Results Among the 34 patients, one got chemotherapy a circle for lack of money, and another got chemotherapy one and a half circle for gastrointestinal hemorrhage. No case was CR. 17 cases were PR. Response rate was 53.1% （17/32）. 6 cases were SD. Rate was 18.8% （6/32）. 9 cases were PD. Rate was 28. 1% （9/ 32 ）. Median time to progression （TIP） was 6 months. Median overall survival time was 10 months. The majority of adverse reactions were nausea, vomiting,diarrhea, leucopenia. Most of them were I /Ⅱdegree. Conclusion Irinotecan combined with capcitabine in treatment of patients with advanced gastric cancer can get better efficacy with manageable adverse reactions and convenient medication.